Tri-substituted imidazole analogues of SB203580 as inducers for cardiomyogenesis of human embryonic stem cells

authored by

Joo Leng Low, Gerrit Jürjens, Jayasree Seayad, Jasmine Seow, Sherwin Ting, Filip Laco, Shaul Reuveny, Steve Oh, Christina L.L. Chai

Abstract

The p38α mitogen-activated protein kinase (MAPK) inhibitor SB203580 had been reported to enhance the cardiomyogenesis of human embryonic stem cells (hESCs). To investigate if tri-substituted imidazole analogues of SB203580 are equally effective inducers for cardiomyogenesis of hESCs, and if there is a correlation between p38α MAPK inhibition and cardiomyogenesis, we designed and synthesized a series of novel tri-substituted imidazoles with a range of p38α MAPK inhibitory activities. Our studies demonstrated that suitably designed analogues of SB203580 can also be inducers of cardiomyogenesis in hESCs and that cell growth is affected by changes in the imidazole structures.

External Organisation(s)

A-STAR
Bioprocessing Technology Institute, Agency for Science Technology and Research
National University of Singapore

Type

Article

Journal

Bioorganic and Medicinal Chemistry Letters

Volume

23

Pages

3300-3303

No. of pages

4

ISSN

0960-894X

Publication date

01.06.2013

Publication status

Published

Peer reviewed

Yes

ASJC Scopus subject areas

Biochemistry, Molecular Medicine, Molecular Biology, Pharmaceutical Science, Drug Discovery, Clinical Biochemistry, Organic Chemistry

Sustainable Development Goals

SDG 3 - Good Health and Well-being

Electronic version(s)

https://doi.org/10.1016/j.bmcl.2013.03.103 (Access: Closed)